Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Provided By GlobeNewswire
Last update: Nov 7, 2024
Global Phase 1 study of CLN-978 in systemic lupus erythematosus (SLE) cleared to initiate in U.S. and Australia; initial clinical data expected in Q4 2025
CLN-619 on-track for initial expansion cohort data in endometrial and cervical cancers in Q2 2025
Read more at globenewswire.comNASDAQ:CGEM (5/1/2025, 10:13:34 AM)
8.13
-0.15 (-1.81%)
Find more stocks in the Stock Screener
